

01205


Paediatric Haematology

Michael L. N. Willoughby

Paediatric Haematology

Michael L. N. Willoughby MA, MD, MRC Path,

Consultant Haematologist
to the Royal Hospital for Sick Children
and Queen Mother's Hospital, Glasgow



CHURCHILL LIVINGSTONE
Edinburgh London and New York 1977

CHURCHILL LIVINGSTONE

Medical Division of Longman Group Limited

Distributed in the United States of America by
Longman Inc., 19 West 44th Street, New York,
N.Y. 10036 and by associated companies,
branches and representatives throughout
the world.

© Longman Group Limited 1977

All rights reserved. No part of this publication
may be reproduced, stored in a retrieval system,
or transmitted in any form or by any means,
electronic, mechanical, photocopying, recording
or otherwise, without the prior permission of the
publishers (Churchill Livingstone, 23 Ravelston
Terrace, Edinburgh, EH4 3TL).

ISBN 0 443 01442 6

Library of Congress Cataloging in Publication Data
Willoughby, Michael L N
Paediatric haematology.

Includes bibliographies.

1. Pediatric hematology.	I. Title.
RJ411.W55	618.9'21'5
	76-49038

Printed in Great Britain by
Cox & Wyman Ltd
London, Tulseham and Reading

Preface

This book is written for all those concerned with the diagnosis and management of blood disorders in children, whether they are primarily paediatricians or haematologists. I have tried to integrate the fundamental molecular, genetic and cell kinetic aspects of each group of disorders with their clinical and haematological manifestations where this is contributory to an understanding of their pathogenesis and management.

A considerable body of documented information has accumulated in these fields over the past few years and I have attempted to provide access to this by reference to key papers and selected reviews or annotations throughout the text, together with a bibliography designed to give 'the way in' to the literature for the worker wishing to pursue some point in greater depth. Where there are divergent or currently unresolved views on a particular topic I have indicated this. On most issues, however, I have stated my own opinion and practice.


The bibliography also serves to give acknowledgement to the many investigators who have contributed to our better understanding of this

complex and rapidly changing subject, including in particular that small band of paediatric haematologists whose contributions recur in chapter after chapter throughout the book.


I am personally indebted to Dr Rosemary Biggs, Professor R. G. Macfarlane and Dr A. A. Sharp of the Radcliffe Infirmary, Oxford, who initiated my interest in haematology, and to my colleagues at the Royal Hospital for Sick Children, Glasgow, who have taught me a little paediatrics! Mr J. Devlin and members of his department of Medical Illustration have generously given much time and effort in the preparation of the original clinical photographs and charts, as well as assisting in the preparation of the photomicrographs. The original X-ray plates have been reproduced by the courtesy of Dr Phillip Rawson and Dr Elizabeth Sweet of the department of Radiology. I especially wish to thank my secretary Mrs Catherine Walker who meticulously decoded my illegible notes into the text which follows.

Glasgow, 1976


M.L.N.W.



A. Megaloblastic Marrow in Juvenile Pernicious Anaemia $\times 540$




B. Infantile Pycnocytois. Peripheral blood $\times 540$



C. Glandular Fever Cell. Peripheral blood $\times 1,000$



D. Leukaemic Lymphoblasts. Marrow $\times 1,000$




E. PAS positive Leukaemic Lymphoblasts. Marrow $\times 1,000$




F. Neuroblastoma Cells in Marrow $\times 540$



G. Reticulum Cells in Marrow. Histiocytosis X. $\times 100$




H. Sea-blue Histiocyte (Lt.) and Nieman-Pick-like Cell (Rt.) in Marrow of child with bizarre neurological syndrome. $\times 540$




I. Gaucher-like Cell in Marrow $\times 540$



J. Cystine Crystals. Marrow in Cystinosis. $\times 540$



K. Reilly Bodies in Lymphocytes in Hurler's syndrome. Peripheral blood $\times 1,000$



L. Vacuolated Lymphocytes in Gm1 Type 1 Gangliosidosis. Peripheral blood $\times 540$

Leishman's stain, apart from PAS stain in E and Neutral Red

Introduction

HAEMATOLOGICAL ASSESSMENT IN CHILDHOOD

Intrinsic handicaps in the practice of paediatric haematology are that 'clean' venepunctures are less dependable than in adults and that it is seldom justifiable to use radioactive isotope techniques to study red cell survival or iron metabolism. In fact almost all haematological investigations can be performed on capillary blood samples including coagulation tests such as the thromboplastin screening test or Factor VIII Assay (Hardisty and Ingram, 1965) providing the technical staff are adequately trained and the laboratory properly orientated to paediatric work. The relative ease of capillary blood sampling makes sequential observations more practical whether at intervals of hours, in monitoring the correction of coagulation disorders, at intervals of days, in assessing the response to haematinics, or at intervals of weeks in the surveillance of chemotherapy as in leukaemia. Many such children can be followed both in remission and relapse for periods of 3 to 5 years with frequent blood tests without recourse to a single diagnostic venepuncture. This policy permits the reservation of veins for therapeutic purposes. A further advantage is that the artefacts of red cell and white cell morphology often seen in anticoagulated blood collected some hours previously is avoided when freshly made blood films from capillary blood are used, and the spurious thrombocytopenia frequently found in 'difficult' venepuncture specimens is obviated. A modification of capillary blood collection using small plastic tubes containing EDTA rather than pipettes has recently been described for paediatric work by Stuart, Barrett and Pragnell (1974). It permits the use of automated cell counting as well as ESR determination by a micromethod. Only 0.5 ml of blood is collected for a number of tests.

It is strikingly informative to graph the therapy and relevant haematological measurements in patients with blood diseases; for example the platelet count in idiopathic thrombocytopenic purpura (ITP), the granulocytes, blast cells and

platelets in leukaemia, and the reticulocytes plus haemoglobin in haemolytic or deficiency anaemias. Consideration of the graph may disclose trends and relationships not otherwise apparent, at the same time giving a better guide as to the appropriate intervals at which future tests should be performed; for instance reticulocyte peaks, response to Factor VIII therapy or the existence of cyclic neutropenia could be entirely missed by haphazard timing of tests.

Marrow examinations are frequently needed in the elucidation of abnormalities of the peripheral blood including all cases of thrombocytopenia, neutropenia, unexplained anaemia or leucoerythroblastic anaemia. It is seldom profitable to examine the bone marrow before considering the peripheral blood findings since few diseases extensively involve the marrow without producing some abnormality of the peripheral blood. Also it may be impossible to evaluate the significance of the marrow findings without a knowledge of the peripheral blood picture and the clinical features (e.g. in ITP). Particularly in leukaemia repeated marrow examinations are of value to assess the response to therapy. The posterior iliac crest is the most consistently useful site over the age of 6-8 weeks; below this age the tibial puncture is used, taking great care to avoid damaging the upper tibial ossification centre.

Normal values

Table 1 shows the range of normal haemoglobin, PCV and MCV over the first 12 weeks of life. At 9 weeks the haemoglobin may fall as low as 9.5 g/100 ml in full-term infants. In premature infants even lower levels are seen viz. mean 9.4 g/100 ml ± 1.0 (S.D.) at 10 weeks (Gorten and Cross, 1964). In a recent annotation on the subject Oski and Stockman (1974) state that apparently healthy premature infants weighing 1.2 kg or less show average haemoglobin levels of 8.0 g/100 ml between 6 and 8 weeks, and that values of 7.0 g/100 ml are frequently seen without recognizable haematological or other disease. From 6 months to puberty there is a gradual rise in haemoglobin and PCV to adult levels (Table 2).

Table 1 Haemoglobin, PCV and MCV in normal full-term infants

Days	No. Cases	Hb g/100 ml \pm S.D.	PCV per cent \pm S.D.	MCV $\mu^3 \pm$ S.D.
1	19	19.0 \pm 2.2	61 \pm 7.4	119 \pm 9.4
2	19	19.0 \pm 1.9	60 \pm 6.4	115 \pm 7.0
3	19	18.7 \pm 3.4	62 \pm 9.3	116 \pm 5.3
4	10	18.6 \pm 2.1	57 \pm 8.1	114 \pm 7.5
5	12	17.6 \pm 1.1	57 \pm 7.3	114 \pm 8.9
6	15	17.4 \pm 2.2	54 \pm 7.2	113 \pm 10.0
7	12	17.9 \pm 2.5	56 \pm 9.4	118 \pm 11.2
Weeks				
2nd	32	17.3 \pm 2.3	54 \pm 8.3	112 \pm 19.0
3rd	11	15.6 \pm 2.6	46 \pm 7.3	111 \pm 8.2
4th	17	14.2 \pm 2.1	43 \pm 5.7	105 \pm 7.5
5th	15	12.7 \pm 1.6	36 \pm 4.8	101 \pm 8.1
6th	10	11.9 \pm 1.5	36 \pm 6.2	102 \pm 10.2
7th	10	12.0 \pm 1.5	36 \pm 4.8	105 \pm 12.0
8th	17	11.1 \pm 1.1	33 \pm 3.7	100 \pm 13.0
9th	13	10.7 \pm 0.9	31 \pm 2.5	93 \pm 12.0
10th	12	11.2 \pm 0.9	32 \pm 2.7	91 \pm 9.3
11th	11	11.4 \pm 0.9	34 \pm 2.1	91 \pm 7.7
12th	13	11.3 \pm 0.9	33 \pm 3.3	88 \pm 7.9

Note the physiological macrocytosis at birth.

Data reproduced by permission of Professor Matoth and the editor, from the paper by Matoth et al. (1971) *Acta Paediat. Scand.*, **60**, 317.

Table 2 Haemoglobin and PCV in children after the age of 6 months

Age	Hb g/100 ml \pm S.D.	PCV per cent \pm S.D.
6 Months	11.5 \pm 0.7	38 \pm 2
12 "	11.9 \pm 0.6	39 \pm 2
1½-3 Years	11.8 \pm 0.5	39 \pm 2
5 "	12.7 \pm 1.0	37 \pm 3
10 "	13.2 \pm 1.0	39 \pm 3
14 "	16.0 \pm 2.0	40 \pm 3
Adult male	16.0 \pm 2.0	47 \pm 5
Adult female	14.0 \pm 2.0	42 \pm 5

Data from Lascari (1973), p. 112.

Reproduced by permission of the author and publishers.

Table 3 Normal leucocyte values and differential counts in childhood

Age	Total WBC $10^3/\text{mm}^3$	Neutrophils		Mean per cent		
		Bands	Segmented	Lymphocytes	Monocytes	Eosinophils
Birth	9-30	9	52	31	6	2
12 hours	13-38	10	58	24	5	2
1 week	5-21	7	39	41	9	4
6 months	6-18	4	28	61	5	3
1 year	6-18	3	28	61	5	3
2 years	6-17	3	30	59	5	3
4 years	6-16	3	39	50	5	3
6 years	5-15	3	48	42	5	3
12 years	5-14	3	52	38	4	3
16 years	5-13	3	54	35	5	3

Data from Lascari (1973), p. 112, and Dittmar and Altman (1961).

Reproduced by permission of Professor Lascari and the publishers.

White cell counts show an absolute and relative lymphocytosis until the age of 4 years, after which adult proportions pertain (Table 3). The absolute number of neutrophils, however, normally remain above $1,500/\text{mm}^3$ during the first 4 years in spite of the relative lymphocytosis at this time.

Platelet counts are normal throughout infancy and childhood (Chap. 16).

Marrow findings are essentially normal through-

out childhood apart from a marked erythroid depression with as low as 7 per cent of normoblasts at the age of 1 month rising to 15 per cent at 3 months, 16 per cent at 6 months and 19 per cent at 1 year, thereafter being indistinguishable from normal (Gairdner *et al.*, 1952; Glaser *et al.*, 1970). Marrow plasma cell counts are low in normal infants and young children, but approach adult levels at 5 years (Steiner and Pearson, 1966).

REFERENCES

- Dittmer, E. S. & Altman, P. L. (1961) *Blood and other fluids*, p. 109, 125. Washington, D.C.: Federation of American Societies for Experimental Biology.
- Gairdner, D., Marks, J. & Roscoe, J. P. (1952) Blood formation in infancy. Part I. The normal bone marrow. *Arch. Dis. Childh.*, **27**, 128.
- Glaser, K., Limarzi, L. R. & Poncher, H. G. (1950) Cellular composition of the bone marrow in normal infants and children. *Pediatrics*, **6**, 789.
- Gorten, M. K. & Cross, E. R. (1964) Iron metabolism in premature infants. II. Prevention of iron deficiency. *J. Pediat.* **64**, 569.
- Hardisty, R. M. & Ingram, G. I. C. (1965) *Bleeding disorders: Investigations and management*. Oxford: Blackwell.
- Lascari, A. D. (1973) *Leukemia in childhood*. p. 112. Springfield, Illinois: Charles C. Thomas.
- Matoth, Y., Zaizor, R. & Varsano, I. (1971) Postnatal changes in some red-cell parameters. *Acta Paediat. Scand.*, **60**, 317.
- Oski, F. A. & Stockman, J. A. (1974) Annotation: Anaemia in early infancy. *Brit. J. Haemat.*, **27**, 195.
- Steiner, M. L. & Pearson, H. A. (1966) Bone marrow plasmacyte values in childhood. *J. Paediat.*, **68**, 562.
- Stuart, J., Barrett, B. A. & Pragnell, D. R. (1974) Capillary blood collection in haematology. *J. clin. Path.*, **27**, 869.

Contents

1. Iron Deficiency Anaemia 1

- Pathogenesis 1
 - Iron endowment at birth 1
 - Iron in the diet 2
 - Gastrointestinal function and iron deficiency 3
- Incidence of iron deficiency 4
- Clinical features 5
- Diagnosis and laboratory findings 5
 - Additional haematological findings 5
 - Biochemical tests of iron deficiency 7
 - Tests for intestinal blood loss 7
- Treatment 8

2. Folate Metabolism and Deficiency 13

- Biochemistry of folic acid and its derivatives 13
- Dietary sources of folate 14
- Absorption of folates 15
- Determination of folate status 16
- Folate assays in blood 16
- Figlu test 17
- Haematological changes 18
 - Peripheral blood 18
 - Marrow 18
- Folate balance in infancy and childhood 19
 - Daily folate requirements 19
 - Folate status in the newborn 20
- Conditions associated with folate deficiency in childhood 21
 - Prematurity 21
 - Infection 22
 - Malabsorption 23
 - Haemolysis 24
 - Nutritional deficiency 25
 - Anticonvulsants and other drugs associated with megaloblastic anaemia 26
 - Inborn errors related to folate metabolism 28
 - Conditions with increased folate loss 29
- Clinical features and treatment 29

3. Vitamin B₁₂ Metabolism and Deficiency 35

- Biochemistry 35
- Absorption and transport 35
- Assessment of B₁₂ status 36
- B₁₂ balance in infancy 37

Classification of B₁₂ deficiency in infancy and childhood 38

- Intrinsic factor deficiency 38
- Selective ileal malabsorption of B₁₂ 39
- Other causes of malabsorption 39
- Nutritional B₁₂ deficiency 40
- Transcobalamin II deficiency 40

4. Aplastic Anaemia 43

- Introduction 43
- Classification 44
- Constitutional aplastic anaemia 45
 - Aetiology 45
 - Clinical features 46
 - Laboratory diagnosis 48
 - Treatment and prognosis 50
- Acquired aplastic anaemia 53
 - Aetiology 53
 - Clinical features 56
 - Laboratory diagnosis 56
 - Association of haemolysis, including PNH 57
 - Treatment 58
 - Androgens 58
 - Prognostic features 60
 - Marrow transplantation 60
 - Miscellaneous therapy 60
- Pure red-cell aplasia 61
 - Aetiology 61
 - Clinical features 62
 - Laboratory diagnosis 63
 - Course and treatment 64

5. Haemolytic Anaemias: General Features 71

- Red-cell changes 71
 - Spherocytes 71
 - Red-cell fragmentation, 73
 - Red-cell survival 73
- Compensatory marrow activity 73
- Pigment metabolism 74

6. Hereditary Haemolytic Anaemias with Characteristic Red-cell Morphology 77

- Hereditary spherocytosis (HS) 78
 - Aetiology and Pathogenesis 78

- Clinical features 78
 - Jaundice 78
 - Anaemia 78
 - Splenomegaly 78
- Laboratory findings 79
- Treatment 80
- Hereditary elliptocytosis (HE) 80
 - Aetiology 80
 - Clinical features 81
 - Laboratory findings 81
 - Treatment 81
- Stomatocytosis 81
- Congenital haemolytic anaemia with dehydrated red cells 82
- Acanthocytosis 83
- Congenital dyserythropoietic anaemias (CDA) 83

7. Hereditary Non-spherocytic Haemolytic Anaemias 89

- Introduction 89
- Biochemical considerations 90
- Disorders of the hexose monophosphate shunt 92
- Glucose-6-phosphate dehydrogenase (G-6-PD) 92
 - Clinical manifestations of G-6-PD deficiency
 - Drug-induced haemolysis 94
 - Favism 96
 - Neonatal jaundice and kernicterus 96
 - Chronic non-spherocytic haemolytic anaemia 97
- Other defects affecting availability of reduced glutathione (GSH) 97
 - 6-phosphogluconate dehydrogenase (6-PGD) 97
 - Glutathione reductase (GSSG-R) 98
 - Glutathione peroxidase (GSH-Px) 98
 - Defects of glutathione (GSH) synthesis 98
- Disorders of the glycolytic pathway (Embden-Meyerhof) 100
 - Pyruvate kinase (PK) 101
 - Hexokinase (HK) 102
 - Phosphohexose isomerase (PHI) 103
 - Phosphofructokinase (PFK) 103
 - Triosephosphate isomerase (TPI) 104
 - Glyceraldehyde-3-phosphate dehydrogenase (G-3-PD) 104
 - Phosphoglycerate kinase (PGK) 104
 - 2, 3-Diphosphoglyceromutase (2, 3-DPGase) 105
 - Adenosine triphosphatase (ATP-ase) 105

8. Abnormalities of Haemoglobin Synthesis 111

- Basic considerations 111
 - Chemical structure of haemoglobin 111
 - Normal variants of haemoglobin 112

- Haemoglobins present at birth 113
- Detection of foetal haemoglobin 113
- Physiological significance of foetal haemoglobin 113
- Postnatal changes in Hb. F concentration 115
- Genetically determined abnormalities of Haemoglobin structure: the Haemoglobinopathies 116
 - Inheritance 117
 - Geographic distribution and incidence 117
 - Sickling states 118
 - Pathogenesis of sickling phenomena and related haemolysis 118
 - Haematological diagnosis 120
 - Clinical manifestations of sickling diseases 121
 - Treatment of sickling disorders 123
 - Unstable Haemoglobins 124
 - Pathogenesis of anaemia in UHHA 125
 - Clinical and haematological features of the unstable haemoglobinopathies 126
 - Management 127
 - M-Haemoglobinopathies, and other causes of Methaemoglobinaemia 127
 - Haematological aspects 127
 - Clinical features 128
 - Diagnosis 129
 - Treatment 129
 - Thalassaemia syndromes 129
 - Biochemical lesions in thalassaemia 129
 - Genetics of different forms of thalassaemia 130
 - Pathogenesis of the anaemia 131
 - Haematological findings and diagnosis 132
 - Age of presentation and early diagnosis 133
 - Clinical features of thalassaemia 134
 - Management 135
- 9. Acquired Haemolytic Anaemias 145
 - Microangiopathic haemolytic anaemia (MAHA) 145
 - Mechanism of burr cell formation. Pathogenesis of MAHA 146
 - Haematological diagnosis 146
 - Red cell membrane disorders 147
 - Lipid accumulation and stagnation 147
 - Acanthocytosis 148
 - Spur cell haemolytic anaemia 148
 - Target cells in liver disease 148
 - Lipid peroxidation and haemolysis 148
 - Relationship to infantile pycnocyctosis 149
 - Changes in membrane plasticity 149
 - Structural defects of red-cell membrane, including dyserythropoietic anaemias 150
 - Autoimmune haemolytic anaemias 150
 - Pathogenesis of the anaemia 151

- Relationship of autoantibodies to underlying disease 151
 Clinical manifestations 152
 Haematological features 152
 Treatment 153
- Drug-induced and toxic haemolysis 154
 Immune drug-induced haemolytic anaemia 154
 'Immune' or drug-haptene type 156
 'Autoimmune' drug-induced type 156
 Haemolytic anaemias due to infection 156
- Hypersplenism 157
 Haemolytic anaemia secondary to systemic disease 157
- 10. Anaemias in the Neonatal Period.**
1. Rhesus Disease (Rhesus Isoimmunisation) 163
 Synonyms 163
 Pathogenesis and Prevention 163
 Antenatal detection and prediction of severity of Rh disease 164
 Clinical findings 168
 Laboratory findings 169
 Management and treatment 170
 Intrauterine transfusion 172
- 11. Anaemias in the Neonatal Period. 2. Abo Haemolytic Disease of the Newborn (Abo Hdnb)** 181
 Pathogenesis 181
 Clinical features 182
 Laboratory findings 182
 Management 183
 Phototherapy and phenobarbitone therapy 183
 Phenobarbitone 183
 Phototherapy 183
 Other blood group incompatibilities 184
- 12. Non-immune Anaemias in the Neonatal Period** 187
 Infantile pycnocytois 188
 Neonatal haemolysis due to infection 190
 Syphilis 190
 Toxoplasmosis and cytomegalovirus 190
 Rubella, Coxsackie B, Herpes simplex, malaria 191
 Bacterial infections 191
 Heinz-body anaemias in the newborn 191
 Neonatal manifestations of hereditary haemolytic anaemias 194
 Hereditary spherocytosis (HS) 194
 Hereditary elliptocytosis (HE) 195
 Hereditary red-cell enzyme defects 195
 Thalassaemias and haemoglobinopathies 195
- Neonatal anaemia due to blood loss 196
 Chronic foetal blood loss 197
 Aplastic anaemia in the neonatal period 198
- 13. Secondary Anaemias** 203
 Anaemias of prematurity 203
 Anaemias due to chronic infections 204
 Rheumatoid arthritis and collagen diseases 206
 Renal failure 207
 Liver disease 208
 Endocrine disorders 208
 Malignant disease and bone marrow encroachment 209
 Marble-bone disease 210
 Sideroblastic anaemias 212
- 14. Polycythaemia** 217
 Primary polycythaemia 217
 Polycythaemia rubra vera 217
 Benign familial polycythaemia (Erythrocytosis) 218
 Secondary polycythaemia 218
 Cyanotic congenital heart disease 218
 Abnormal haemoglobins 219
 Tumours and renal disease 219
 Neonatal polycythaemia 219
- 15. Disorders of Granulocytes, Monocytes and Lymphocytes** 223
 Neutropenia and Agranulocytosis 223
 Granulocyte kinetics and distribution 223
 Hereditary forms of neutropenia and agranulocytosis 225
 Infantile genetic agranulocytosis (IGA) 225
 Familial benign chronic neutropenia 227
 Reticular dysgenesis (congenital aleucocytosis) 227
 Chronic benign granulocytopenia of childhood (CG) 227
 Ineffective myelopoiesis 229
 Cyclic Neutropenia 229
 Lazy-leucocyte syndrome 231
 Neutropenia associated with agammaglobulin-
 aemia and dysglobulinaemia 231
 Neutropenia associated with pancreatic
 insufficiency 231
 Neutropenia associated with inborn errors of
 metabolism 232
 Drug-induced neutropenia 232
 Neutropenia secondary to peripheral
 sequestration 233
 Immunoneutropenias 233
 Other causes of neutropenia 233

- Disorders of phagocyte function 234
- Physiology of neutrophil granulocytes 234
- The biochemical defect in CGD and related disorders 235
- NBT test in diagnosis of CGD and related conditions 236
- Pathology of CGD 236
- Clinical features of CGD and related disorders 236
- Inheritance of CGD 237
- Other abnormalities of phagocytic function 237
- Myeloperoxidase deficiency 237
- Job's syndrome 237
- Leukocyte glutathione peroxidase deficiency 238
- G-6-PD deficiency in leucocytes 238
- Chédiak-Higashi disease 238
- Congenital abnormality of specific granule formation 238
- Acquired disorders of leukocyte function 238
- Leukocyte changes secondary to infection 239
- Infectious mononucleosis and related conditions 242
- Infectious lymphocytosis 245
- Eosinophilia 245
- 16. Thrombocytopenia 253**
- The platelet count 253
- Normal platelet life-span and sequestration 254
- Kinetics of thrombopoiesis 255
- Morphological aspects of thrombopoiesis 256
- Platelet size as a measure of thrombopoiesis 256
- Classification of thrombocytopenias 257
- Idiopathic thrombocytopenic purpura (ITP) 257
- Nature of ITP 257
- Difficulty in consistent demonstration of autoantibody 258
- Site of platelet destruction in vivo 259
- Course of ITP in children 260
- Clinical features 260
- Haematological findings 261
- Diagnosis 261
- Management of childhood ITP 262
- Thrombocytopenia in the neonatal period 264
1. Secondary to maternal ITP 264
2. Isoimmune neonatal purpura 265
3. Secondary to maternal drug ingestion 267
4. Intrauterine or neonatal infection 267
5. Other causes of platelet consumption 268
6. Congenital megakaryocytic hypoplasia 268
- (a) Bilateral absent radii (TAR) 268
- (b) Fanconi's anaemia 271
- (c) Trisomy syndromes 271
7. Hereditary thrombocytopenias 271
- (a) Wiscott-Aldrich syndrome (WAS) 271
- (b) Sex-linked recessive thrombocytopenia 272
- (c) Autosomal thrombocytopenias 273
- May-Hegglin 273
- Dominant 274
- Recessive 274
8. Metabolic causes of neonatal thrombocytopenia 275
9. Congenital leukaemia 275
- Drug-induced thrombocytopenia 275
- Mechanism of drug-haptene disease 275
- Post transfusion thrombocytopenic purpura 278
- Thrombopoietin deficiency 278
- Cyclical thrombocytopenia 278
- Hypersplenism 279
- MAHA and DIC 279
- Marrow encroachment 279
- Thrombocytosis 279
- 17. Defects of Platelet and Capillary Function 287**
- Normal platelet function 287
- Tests of platelet function 288
- Bleeding time 288
- Platelet size and morphology 289
- Platelet aggregation and ADP release in vitro 290
- Platelet adhesion to glass beads 291
- Clot retraction 292
- Platelet factor 3 (PF-3) availability 292
- Inherited disorders of platelet function 293
- Glanzmann's thrombasthenia 293
- Thrombopathia (or defects of ADP release) 293
- Bernard-Soulier syndrome 294
- May-Hegglin anomaly 295
- Von Willebrand's disease 295
- Congenital afibrinogenemia 298
- Acquired defects of platelet function 298
- Drug ingestion 298
- Platelet function in the newborn 299
- Uraemia 300
- Liver disease, dysproteinemia 300
- Platelet transfusion 301
- Non-thrombocytopenic purpura 302
- Anaphylactoid purpura (Henoch-Schönlein syndrome) 302
- Scurvy 303
- Drug, foods and infections 303
- Inherited vascular and connective tissue disorders 303
- Hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease) 303
- Ehler-Danlos syndrome 303

Pseudoxanthoma elasticum and osteogenesis imperfecta 304

18. Coagulation Disorders. I. Hereditary 309

Physiology of blood coagulation 309

Investigation of disorders of coagulation 311

Hereditary coagulation defects 313

Haemophilia 313

Incidence 314

Inheritance 315

Newer knowledge regarding the nature of antihaemophilic factor 315

Clinical manifestations 316

Diagnosis 317

Management 319

Correction of the coagulation deficiency 319

Use of plasma, cryoprecipitate and concentrates 320

1. Fresh or fresh-frozen plasma 320

2. Cryoprecipitate 320

3. Concentrates of factors VIII and IX 321

Management of specific problems 321

1. Cuts and lacerations 321

2. Soft tissue bleeding 322

3. Haemarthrosis 322

4. Nosebleeds 322

5. Haematuria 323

6. Gastrointestinal bleeding 323

7. CNS bleeding 323

8. Dental treatment 323

9. Surgery in haemophilia 324

10. Injections and immunization 324

11. Home transfusion and prophylactic treatment 324

12. Treatment of pain in haemophilia 325

13. Treatment of patients who have developed inhibitors 326

Other hereditary coagulation disorders 327

Defects of the contact phase of coagulation (factors XI and XII) 327

Deficiencies of factors in the prothrombin complex (factors II, V, VII and X) 327

Defects of fibrinogen and fibrin stabilization (factors I and XIII) 329

19. Coagulation Disorders II. Acquired 335

Impaired hepatic synthesis 335

Vitamin K 335

Coagulation status in the newborn 336

Haemorrhagic disease of the newborn 338

Intrapartum and perinatal bleeding 339

Maternal drug ingestion 339

Diagnosis 340

Treatment 340

Vitamin K deficiency beyond the neonatal period 341

Hepatocellular disease 342

Disseminated intravascular coagulation (DIC) 343

Fibrin degradation products (FDPs) 344

Diagnosis of DIC 345

General considerations 346

Specific therapy for DIC 346

Heparin therapy 347

Control and dosage of Heparin 347

DIC in the neonatal period 349

Prematurity 350

Asphyxia and acidosis 350

Hypothermia 350

Infection 350

Severe rhesus disease 350

Respiratory distress syndrome 351

Maternal and intrauterine causes of neonatal DIC 352

Causes of intravascular coagulation beyond the newborn period 352

Renal vein thrombosis and hypertonic dehydration 352

Giant haemangioma (Kasabach-Merritt syndrome) 353

Congenital heart disease (CHD) 354

Post-operative haemorrhage after cardiac surgery 355

Other vascular disorders 355

The haemolytic uraemic syndrome (HUS) 356

Age incidence 356

Clinical features 356

Haematological findings 356

Coagulation investigations 357

Treatment 358

Thrombotic thrombocytopenic purpura (TTP) 359

Septicaemia—bacterial, viral, fungal, rickettsial, protozoal 359

Purpura fulminans 361

Miscellaneous causes of DIC:

Acute liver failure, disseminated malignancy, acute intravascular haemolysis 362

Acquired inhibitors of coagulation 363

20. Leukaemia and Related Disorders 373

Incidence of leukaemia in childhood 373

Aetiology of leukaemia 374

Cell kinetic considerations 377

Diagnosis of acute leukaemia 379

Haematological findings in acute leukaemia 380

Management of acute leukaemia 383

Remission induction 383	Eosinophilic and basophilic leukaemia 402
Supportive treatment during remission induction 387	Chronic monocytic leukaemia (CMOL) 403
CNS prophylaxis 391	Leukaemia reticuloendotheliosis 403
Treatment of overt meningeal leukaemia 391	Leukaemic transformation of reticulososes 403
Maintenance therapy 394	Congenital leukaemia 404
Factors affecting prognosis 397	Non-leukaemic disorders with infiltration of the marrow 405
Age at diagnosis 397	Metastatic malignant infiltration of the marrow 405
Race 397	Myelomatosis 406
White-cell count at diagnosis 397	Letterer-Siwe disease 406
Degree of tissue infiltration 398	Familial erythrophagocytic lymphohistiocytosis (FEL) 408
Cytological features 398	Histiocytic medullary reticulosis (HMR) 408
Unusual types of childhood leukaemia 399	Storage diseases 409
Chronic myelocytic leukaemia (CML) 399	Sea-blue histiocyte syndrome 410
Erythroleukaemia (Di Guglielmo's syndrome) 401	Myelofibrosis 411
Promyelocytic leukaemia 402	Familial myeloproliferative disease 411
Chronic lymphocytic leukaemia (CLL) 402	

I. Iron Deficiency Anaemia

Pathogenesis, Iron endowment at birth, Iron in the diet, Gastrointestinal function / Incidence of iron deficiency / Clinical features / Diagnosis and laboratory findings, Additional haematological findings, Biochemical tests of iron deficiency, Tests for intestinal blood loss / Treatment

This is the commonest form of anaemia seen in paediatric practice. The maximum incidence occurs between 6 months and 3 years of age.

PATHOGENESIS

The prime cause is exhaustion of the neonatal iron stores at a time when the demands of an increasing blood volume and red cell mass are exceeding dietary intake and absorption.

Iron endowment at birth

Over 75 per cent of the total body iron of the newborn is accounted for by its circulating haemoglobin (Table 1.1). This in turn is dependent upon

weight, Osgood, 1955). After birth there is a relatively more rapid growth rate and increase in blood volume in premature as compared to full-term infants (e.g. the birth weight is doubled much earlier in the premature infant). Schulman (1961) has calculated (Table 1.2) that the full-term infant requires a total of 156 mg. of absorbed iron over its first year if it is to have an 'ideal' haemoglobin level 12.3 g/100 ml at the age of 1 year. A premature infant of 1.5 kg would require nearly twice this amount of iron over the year in order to achieve the same level of haemoglobin. (The figure of 12.3 g haemoglobin/100 ml used in this calculation was derived from earlier work by Sturgeon (1956) showing that this was the mean haemoglobin level at one year in a group of children

Table 1.1 Total body iron at birth in term and premature infants

Maturity	B.wt.	Hb g/100 ml	Hb mass	Hb Fe	Storage Fe	Tissue Fe	Total Fe
Full term	3.3 kg	19.0	55 g	185 mg	34 mg	23 mg	242 mg
Premature	1.5 kg	19.0	30 g	97 mg	15 mg	10 mg	122 mg
Deficit at birth = 120 mg							

From Schulman (1961) *J.A.M.A.*, 175,, 118.

two factors: (a) the blood volume, which is proportional to the birth weight (85 ml/kg body wt.), and (b) the haemoglobin concentration at birth, polycythaemic by normal standards. Either low birth weight or a low haemoglobin concentration in the neonatal period result in a proportionately impoverished iron endowment for the newborn infant. Instead of the neonatal iron stores being adequate to meet haemopoietic requirements for 4-6 months, as in the normal infant, they become prematurely exhausted leading to iron deficiency.

In premature or multiple births the iron stores are diminished in direct proportion to the birth weight (75 mg of elemental iron per kg body

rendered iron-sufficient by the administration of 250 mg parenteral iron at 9 months.)

In fact there are two main periods when the premature infant may experience a fall in haemoglobin concentration. The early phase begins in the first week of life and may last to 4 months of age. Very little erythropoiesis is occurring during the first two months of either normal or premature infants and this 'early' anaemia of prematurity is caused by the disproportionately rapid increase in blood volume occurring at a time when there is little red cell production (Gairdner, Marks and Roscoe, 1955). The red cells are normochromic and normocytic (Hadley and Chinnook, 1954).

Table 1.2. Total body iron at 1 year compared to endowment at birth

B.wt.	Hb g/100 ml	Hb mass	Hb Fe	Storage Fe	Tissue Fe	Total Fe
10.5 kg	12.3	103 g	325 mg	0	73 mg	398 mg
Full-term infant required $398 - 242 = 156$ mg over year						
Premature infant required $398 - 112 = 276$ mg over year						

From Schulman *J.A.M.A.*, **175**, 118 (1961).

The second fall in haemoglobin concentration begins in the fourth or fifth months and has the features of a hypochromic iron deficiency anaemia. This 'late' anaemia of prematurity can be prevented by prophylactic iron supplementation (Gorten and Cross, 1964).

A low haemoglobin level in the neonatal period, similarly leading to a reduced endowment of iron stores, can be caused by a large foeto-maternal haemorrhage at delivery, by haemorrhage from one twin to another (twin transfusion syndrome between monochorial foetuses) or by intrapartum foetal blood loss from such causes as rupture of the umbilical cord, anomalous placental vessels, *placenta previa* or *abruptio placentae*. Exchange transfusion may also cause a reduction in the infant's red cell mass by replacing the normally polycythaemic infant's blood by banked blood having a lower haematocrit. Over-enthusiastic diagnostic venepunctures may occasionally cause anaemia, bearing in mind that the blood volume of the newborn is in the region of 250 ml. Chronic foeto-maternal haemorrhage is the unique cause of a hypochromic anaemia due to established iron deficiency at birth. Maternal iron deficiency probably never causes anaemia in the newborn infant (Lanzkowsky, 1961), although extreme degrees of maternal iron deficiency anaemia, e.g. 5.2 g/100 ml, may be associated with the development of anaemia in the infant at about one year (Strauss, 1933), presumably due to a reduction of foetal storage iron in these exceptional circumstances.

The Committee of Nutrition of the American Academy of Paediatrics (1969) have emphasized that it is a simple matter to identify the infants who are poorly endowed with iron stores from a consideration of (a) their birth weight and (b) their haemoglobin levels at the age of a few days. There is a greater need for iron supplements in the poorly endowed infant than in the well-endowed infant and therapeutic recommendations are given for these two groups (*vide infra*).

Iron in the diet

Milk, the natural food of the infant, contains negligible amounts of iron. The concentration is

0.5 mg/l for cow's milk and 1.5 mg/l for human. About 15 litres (or US Quarts) of milk per day would have to be consumed to provide for the iron requirements of normal infants during their first year of life. (Committee on Nutrition, 1969). Most of the naturally occurring dietary iron is derived from fruit, eggs, meat and vegetables and it is only when mixed feeding is introduced that natural




Fig. 1.1 Median total daily dietary iron intake and amounts contributed by various foods during infant development. (Reproduced by permission of Dr Beal and the Editor from the paper by Beal, Myers and McCammon (1962) *Paediatrics*, **30**, 518).

dietary iron becomes appreciable (Fig. 1.1). Only approximately 10 per cent of this dietary iron is absorbed (Schulz and Smith, 1958). The dietary requirement of elemental iron at 6 months has been estimated at 7–8 mg per day by Schulman (1961). This is similar to the recommendation of 1.0 mg/kg per day for well-endowed normal infants (Committee on Nutrition, 1969). It can be seen that this figure is seldom achieved from natural sources alone (Fig. 1.1). The current availability of iron-fortified infant cereals and milk formulae (Table 1.3) simplifies the satisfaction of these iron requirements. Up to 80 per cent of the total iron ingested over the first 6 months of life may be

Table 1.3 Iron content of certain infant feeds

Milk product	Iron in mg/100 ml*
National Dried Milk ($\frac{1}{2}$ cream or full cream)	0.66
Cow and Gate Babymilk 1 and 2	0.50
Cow and Gate 'Premium'	0.65
Cow and Gate 'Ready to Feed' ($\frac{1}{2}$ cream or full cream)	0.40
Ostermilk One	1.03
Ostermilk Two or 'Golden'	1.20
Ostermilk 'Ready to Feed' ('Golden' or 'New')	1.00
SMA 'Ready to Feed' or SMA S26	0.80
Human milk	0.15
Cow's milk	0.10

* Made up according to manufacturer's instructions. Around 150 to 200 ml/kg body wt./day taken in first 5-6 months.

Data largely from D.H.S.S. Report No. 9 (1974) 'Present-Day Practice in Infant Feeding'. London: H.M.S.O.

derived from these enriched sources. Although these products are available they are not always used. Ordinary cow's milk is often given instead. In the opinion of Diamond and Naiman (1967) continued or excessive milk administration, 'milkomania', due to poverty or ignorance, is the single most important cause of iron deficiency developing in the full-term infant.

An excellent recent commentary upon iron-fortified formulas in infancy, the incidence of iron deficiency and inter-relation between iron therapy and vitamin E deficiency is that of Pearson (1971).

Gastrointestinal function and iron deficiency

Occult gastrointestinal blood loss, accompanied by hypoproteinaemia, hypocupraemia and microscopic changes in the duodenal villi have been shown to occur in association with iron deficiency anaemia by the use of ^{51}Cr or ^{59}Fe -labelled red cells, this technique being more sensitive than direct chemical tests on the stools (Hoag, Wallerstein and Pollycove, 1961). Such blood loss may be attributed to the diffuse enteropathy described in children with nutritional iron deficiency by Naiman, Oski, Diamond, Vawter and Schwachman (1964). These authors demonstrated that children with iron deficiency had a high incidence of achlorhydria, impaired absorption of xylose and vitamin A with steatorrhoea and histological evidence of chronic duodenitis and mucosal atrophy. Following treatment with oral iron most of the abnormalities disappeared, suggesting that these were the effect rather than the cause of the iron deficiency.

An alternative theory has followed from the work of Wilson, Heiner and Lahey (1962) who found precipitins to milk protein in the sera of 75-80 per

cent of iron deficient infants aged 6-24 months, together with loss of serum proteins into the gut. Subsequently Lahey and Wilson (1966) have presented evidence that gastro-intestinal blood loss may be induced by ingestion of whole cow's milk in infants possessing antibodies to milk proteins. In some of their patients the administration of milk was the triggering factor leading to a recurrence of blood loss in spite of previous correction of the anaemia by iron therapy. Milk-induced gastrointestinal loss of ^{131}I -labelled serum albumen was similarly found in 7 of 12 iron deficient infants (7-17 months) by an independent group (Woodruff, Wright and Wright, 1972). Further observations by Wilson, Lahey and Heiner (1974) suggest that enteropathy induced by cow's milk occurs in about 50 per cent of young children (6-25 months) with severe iron deficiency anaemia (Hb 2.4-7.7 g/100 ml). Transient allergy to bovine serum protein related to development of gastrointestinal immunity appears to be the cause. This subject has recently been reviewed (B.M.J., 1972).

An unexpected role of acute gastroenteritis in the genesis of infantile anaemia and iron deficiency has been suggested by Elian, Bar-Shani, Liberman and Matoth (1966). Using ^{51}Cr -labelled red cells they found considerably greater blood loss in infants with gastroenteritis (0.7 to 4.8 ml/day, mean 1.85 ml) compared to controls (mean 0.64 ml) or infants with other infections (mean 0.43 ml). (One ml of blood contains approximately 0.5 mg of elemental iron.) They found that anaemia at the age of 1 year was more closely correlated with a history of recurrent diarrhoea than with a poor diet. Intestinal infestation, particularly with hookworm in appropriate geographical areas, can similarly be an important cause of blood loss and anaemia.